Xphyto Therapeutics 

$0.28
24
-$0.13-31.12% Wednesday 21:44

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

28NovExpected
Q1 2021
Q2 2021
Q3 2021
Q1 2022
Q2 2022
Q3 2022
-0.07
-0.05
-0.03
-0.01
Expected EPS
N/A
Actual EPS
-0.0177

Financials

-7,258.68%Profit Margin
Unprofitable
2019
2020
2021
226,083.76Revenue
-16.41MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XPHYF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap19.48B
Illumina provides sequencing and array-based solutions for genetic analysis, directly competing in the genomics space with BioNxt Solutions' focus on next-generation sequencing technologies.
Thermo Fisher Scientific
TMO
Mkt Cap182.57B
Thermo Fisher Scientific offers a broad range of biotechnology product development services, including genomics and proteomics, which overlaps with BioNxt Solutions' offerings in life sciences and diagnostics.
Pacific Biosciences of California
PACB
Mkt Cap404.68M
Pacific Biosciences specializes in long-read sequencing technologies, which competes with BioNxt Solutions' efforts in advanced genomic sequencing solutions.
Qiagen NV
QGEN
Mkt Cap8.46B
Qiagen provides sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, competing in the molecular diagnostics and research markets with BioNxt Solutions.
Bio-Rad Laboratories
BIO
Mkt Cap7.56B
Bio-Rad Laboratories offers products and systems used to separate complex chemical and biological materials, directly competing with BioNxt Solutions in the life sciences research and clinical diagnostics markets.
Agenus
AGEN
Mkt Cap127.87M
Agenus is involved in the discovery and development of immunotherapies, which competes with BioNxt Solutions' work in biotechnological solutions for healthcare, particularly in the development of diagnostics and treatments.
Guardant Health
GH
Mkt Cap12.31B
Guardant Health focuses on liquid biopsies and cancer diagnostics, competing with BioNxt Solutions in the development of advanced diagnostics for cancer and other diseases.
Adaptive Biotechnologies
ADPT
Mkt Cap2.28B
Adaptive Biotechnologies is engaged in the immune-driven medicine space, which competes with BioNxt Solutions' focus on innovative healthcare solutions, particularly in diagnostics and research.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is focused on the development of gene-based medicines, competing with BioNxt Solutions in the area of genetic research and potential therapeutic applications.

About

Health Technology
Pharmaceuticals: Other
BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, thin film drug formulation, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Show more...
CEO
Mr. Hugh A. D. Rogers B.Sc., LL.B
Country
CA
ISIN
CA98421R1055
WKN
000A2PPTN

Listings

0 Comments

Share your thoughts

FAQ

What is Xphyto Therapeutics stock price today?
The current price of XPHYF is $0.28 USD — it has decreased by -31.12% in the past 24 hours. Watch Xphyto Therapeutics stock price performance more closely on the chart.
What is Xphyto Therapeutics stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Xphyto Therapeutics stocks are traded under the ticker XPHYF.
What were Xphyto Therapeutics earnings last quarter?
XPHYF earnings for the last quarter are -0.01 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Xphyto Therapeutics revenue for the last year?
Xphyto Therapeutics revenue for the last year amounts to 226,083.76 USD.
What is Xphyto Therapeutics net income for the last year?
XPHYF net income for the last year is -16.41M USD.
In which sector is Xphyto Therapeutics located?
Xphyto Therapeutics operates in the Healthcare sector.
When did Xphyto Therapeutics complete a stock split?
Xphyto Therapeutics has not had any recent stock splits.
Where is Xphyto Therapeutics headquartered?
Xphyto Therapeutics is headquartered in Vancouver, CA.